Introduction
============

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-associated mortality worldwide, and adenocarcinoma (ADC) is its most common histological subtype ([@b1-ol-0-0-10431]). Despite multiple treatment modalities, NSCLC is commonly associated with unfavorable outcomes, and has a 5-year survival rate of \<20% ([@b1-ol-0-0-10431]). Several factors are known to contribute to the poor prognosis of patients with NSCLC, including late diagnosis of disease and a lack of effective drugs ([@b2-ol-0-0-10431]). NSCLCs are a clinically and molecularly heterogeneous group of diseases, and survival outcome or treatment response varies among individuals ([@b3-ol-0-0-10431]). Therefore, the absence of clinically informative biomarkers for stratifying different risk subgroups or guiding targeted treatment decisions is also notable. Efforts to identify potential biomarkers have been made, with a focus on genetic alterations including somatic mutations, copy number variations and gene expression; however, few are suitable for routine use in the field of NSCLC treatment ([@b3-ol-0-0-10431]--[@b5-ol-0-0-10431]).

Epigenetic changes, and particularly those at the DNA methylation level, are implicated in tumor initiation and progression ([@b6-ol-0-0-10431]). Hypermethylation of CpG islands (CGI) at the promoter regions of tumor-suppressor genes and consequent transcriptional silencing represents the best-known epigenetic event in cancer biology ([@b6-ol-0-0-10431]). As a novel molecular candidate for cancer biomarker discovery, DNA methylation has numerous advantages over the genetic alteration- or gene expression-based biomarkers for clinical application, including reliable DNA samples, stable methylation changes, informative biological relevance and drug-induced reversibility ([@b7-ol-0-0-10431]). Early efforts with candidate-gene approaches have identified a number of useful prognostic biomarkers based on the CGI methylation status of key genes, including Ras association domain family 1 isoform A (*RASSF1A*), runt-related transcription factor 3, and deleted in esophageal and lung cancer 1, in NSCLC ([@b8-ol-0-0-10431]). Unfortunately, these single-gene methylation events were unable to demonstrate consistent prognostic ability in independent validation studies, and therefore have not effected a real change in routine practice ([@b8-ol-0-0-10431]). High-throughput genome-wide DNA methylation profiling techniques have been increasingly used for the detection of the cancer genome markers. These methods may provide a comprehensive and unbiased identification of prognostic DNA methylation events throughout the epigenome, eventually leading to the improvement of personalized medicine for NSCLC ([@b3-ol-0-0-10431]).

The present study aimed to identify clinically useful epigenetic biomarkers from lung ADC-specific CGI methylation changes at different gene regions using genome-wide DNA methylation microarray data of lung ADCs and matched normal tissues from 6 publically available datasets. Accordingly, a 9-CpG CGI methylation panel and hypomethylation/overexpression of ribosomal protein 39 like (*RPL39L*) were identified, which may be of potential value for optimizing the risk stratification and personalized management of lung ADCs.

Materials and methods
=====================

Public datasets
---------------

### The Cancer Genome Atlas (TCGA)

Genome-wide DNA methylation data and corresponding clinical information were retrieved from TCGA data portal (<https://tcga-data.nci.nih.gov/tcga/>, accessed March 2016), including a dataset of 65 lung ADCs \[female/male, 35/30; Tumor-Node-Metastasis (TNM) staging, I to IV ([@b1-ol-0-0-10431]); median age, 67 years; age range, 38--84 years\] and 24 matched non-tumor lung samples assayed using an Illumina Infinium 27k BeadChip system (TCGA-27k set) and a dataset of 456 tumor samples \[female/male, 244/212; TNM staging, I to IV ([@b1-ol-0-0-10431]); median age, 66 years; age range, 33--88 years\] and 29 matched normal samples assayed using a Illumina Infinium 450k BeadChip system (TCGA-450k set) ([@b3-ol-0-0-10431]). There were Infinium 27k and 450k DNA methylation data for 6 tumor samples. For the transcriptome data, Level 3 Illumina HiSeq_RNASeqV2 data were obtained for all tumor samples from the TCGA-27k set, and for 452 tumor samples and 58 matched normal samples from the TCGA-450k set. Among the aforementioned TCGA datasets, Level 2 IlluminaGA_DNASeq data were also available for 490 samples, and Level 3 Affymetrix Genome_Wide_SNP_6 data for 512 samples. Somatic copy number data were analyzed within the GISTIC2.0 module on GenePattern (<http://genepattern.broadinstitute.org/gp/>; accessed March 2016). An amplitude threshold of ±0.2 was used.

### Gene Expression Omnibus (GEO)

Genome-wide DNA methylation microarray data were also obtained from 4 GEO series (<https://www.ncbi.nlm.nih.gov/geo/>; access at March 2016), including: i) A dataset of 59 matched lung ADCs \[female/male, 45/14; TNM stage I to IV ([@b1-ol-0-0-10431]); median age, 68 years; age range, 39--86 years\] and non-tumor lung samples \[accession no. GSE32861; Selamat *et al* set ([@b9-ol-0-0-10431])\]; ii) a dataset of 26 matched tumor \[female/male, 14/12; TNM stage I to IV ([@b1-ol-0-0-10431]); median age, unknown\] and normal lung samples \[accession no. GSE32866; Ontario Tumor Bank set ([@b9-ol-0-0-10431])\]; iii) a dataset of 28 matched tumor \[female/male, 22/6; TNM stage I to IV ([@b1-ol-0-0-10431]); median age, 65 years; age range, unknown\] and normal lung samples of never-smokers \[accession no. GSE62948; Mansfield *et al* set ([@b10-ol-0-0-10431])\]; and iv) a dataset of 35 matched tumors \[female/male, 19/16; TNM stage I to II ([@b1-ol-0-0-10431]); median age, 63 years; age range, 47--88 years\] and normal lung samples of patients with lung ADCs \[accession no. GSE63384; Robles *et al* set ([@b11-ol-0-0-10431])\].

### Ethical approval

All procedures performed in studies involving humans were conducted in accordance with the ethical standards of the institutional research committees and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants as reported by included datasets ([@b3-ol-0-0-10431],[@b9-ol-0-0-10431]--[@b11-ol-0-0-10431]).

### Microarray data processing

For the Level 3 DNA methylation microarray data (Infinum BeadChips, Illumina Inc.), the methylation level of each interrogated CpG locus was summarized as a β-value, providing a continuous and quantitative index of DNA methylation, ranging from 0 (completely unmethylated) to 1 (completely methylated). To ensure that β-values were comparable across each dataset/platform, batch effects were adjusted by a non-parametric empirical Bayes approach (*ber* R package; version 3.2.5; <http://www.r-project.org/>) ([@b12-ol-0-0-10431]--[@b14-ol-0-0-10431]). The empirical Bayes correction was demonstrated to effectively remove batch effects following initial microarray data normalization ([@b12-ol-0-0-10431],[@b13-ol-0-0-10431]). M-value transformation was applied prior to the batch effect adjustment to avoid a negative β-value, as described previously ([@b15-ol-0-0-10431]). For the gene-level analysis of the Level 3 Illumina HiSeq_RNASeqV2 data, expression values of 0 were set as the overall minimum value, and all data were log~2~ transformed and standardized to z-scores within each gene. All missing values were imputed by nearest neighbor averaging (*impute* R package) ([@b3-ol-0-0-10431]).

### Cancer-specific CGI methylation loci and their correlation with gene expression

The CpG probes interrogated by the Infinium 27k and 450k platforms were maintained for analysis, and were annotated using the Infinium Human Methylation 450k annotation file. Prior selection of CpGs probes was performed by removal of those that: i) Targeted the X and Y chromosomes; ii) contained a single-nucleotide polymorphism within 5 base pairs of and including the targeted CpGs; and iii) were not located at CGI regions of a gene; CGI was defined by the UCSC genome reference (<http://genome.ucsc.edu/>; accessed March 2016). For CpGs corresponding to multiple annotation terms, the first one in the 450k annotation file were used in the present study, to simplify data interpretation. Finally, a total of 9,270 CpG probes were included for additional analysis. Differentially methylated CpGs were computed by two-sample Wilcoxon test (*samr* R package). Lung ADC-specific CpGs were defined as those having a median β difference ≥0.2 between matched tumor and non-tumor lung samples and a false discovery rate (FDR) q-value ≤0.05 in at least 4 of the 6 datasets. Methylation and expression data were paired based on each Entrez Gene ID (<https://www.ncbi.nlm.nih.gov/gene/>; accessed March 2016). The correlation between methylation and expression level of each gene was evaluated by Pearson\'s correlation analysis, and those having an absolute Pearson correlation coefficient (r)≥0.3, 0.2--0.3, or 0.1--0.2 and P≤0.05 were defined as strong, moderate or weak correlations, respectively.

### Construction and validation of a CGI methylation-based risk score signature

The training-validation approach was used to construct a prognostic CGI methylation signature. The training phase was performed using the TCGA-450k set, where the methylation levels of lung ADC-specific CpGs were correlated with overall survival (OS) time by univariate Cox regression analysis with permutation correction within the Biometric Research Branch-Array Tools (<http://brb.nci.nih.gov/BRB-ArrayTools>, accessed March 2016). Those that exhibited significant correlation with OS (permutation P≤0.05), and high variability \[standard deviation (SD)≥0.10\] were finally selected as prognostic methylation candidates. Probes with a higher SD variability indicated that the interrogated CpGs loci may have more opportunities to be dysregulated across tumors. These CpGs may therefore be more likely to serve roles in tumor biology, and the alterations in those CpGs may be easier to detect ([@b16-ol-0-0-10431]). The prognostic model was established by risk-score analysis, where each patient was assigned a risk score that is a linear combination of the methylation levels of each CpG weighted by their corresponding Cox regression coefficients ([@b17-ol-0-0-10431]). The median risk score (3.08) from the training set was pre-specified as cut-off for stratifying low-risk and high-risk subgroups. The validation phase was performed on the aforementioned TCGA-27k ([@b3-ol-0-0-10431]) and Robles *et al* ([@b11-ol-0-0-10431]) datasets. An additional dataset of patients with lung ADC \[female/male, 127/125; TNM stage I to IV ([@b1-ol-0-0-10431]); median age, 65 years; age range, 40--90 years\] with relapse-free survival (RFS) time was also included for independent validation \[accession no. GSE39279; n=252; Sandoval *et al* set ([@b2-ol-0-0-10431])\].

### Database for Annotation, Visualization and Integrated Discovery (DAVID) annotation clustering analysis

DAVID (version 6.7; <https://david.ncifcrf.gov/>; accessed March 2016) ([@b18-ol-0-0-10431]) was used to create functional annotation for genes corresponding to cancer-specific differentially-methylated CpGs with Gene Ontology ([@b19-ol-0-0-10431]), BioCarta ([@b20-ol-0-0-10431]) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway tools ([@b21-ol-0-0-10431]).

### Statistical analysis

Survival data were estimated by the Kaplan-Meier method, and compared using the log-rank test. Survival data were summarized as median OS time or RFS time. The associations between variables and survival data were evaluated using the univariate Cox regression model. A multivariate Cox regression model was used to evaluate the independence of each potential prognostic indicator by incorporating those significant variables from the univariate Cox model. Pooled survival data were analyzed by meta-analysis with the inverse-variance method, where either fixed- or random-effect models were used on the basis of the intra-dataset heterogeneity. Heterogeneity was analyzed using the χ^2^ test and I^2^ statistic, with P~heterogeneity~ \<0.1 or I^2^ value \>50% being considered significant. When integrating the DNA methylation and gene expression data of *RPL39L*, the optimal cut-off values to segregate patients into poor and good prognostic subgroups were determined by the maximally selected rank statistics, as described previously ([@b22-ol-0-0-10431]). All calculations were performed with SPSS v19.0 (SPSS Software, Inc., Chicago, IL, USA) and R software version 3.2.5, and P≤0.05 was considered to indicate a statistically significant difference.

Results
=======

### Identification of cancer-specific CGI methylation loci in lung ADCs

By comparing the genome-wide DNA methylation data of matched lung ADCs and non-tumor tissues from the 6 included datasets, a total of 134 CGI loci (corresponding to 119 genes) that met the study criteria of lung ADCs-specific methylation changes were identified. Almost all of these CGI CpGs gained DNA methylation, whereas only 3 loci (\[cg07693270 (*RPL39L*); cg24898753 (ferritin heavy chain 1); and cg06038133 (*CORO6*)\] were hypomethylated in lung ADCs ([Table I](#tI-ol-0-0-10431){ref-type="table"}). DAVID annotation analysis ([@b18-ol-0-0-10431]) revealed that those cancer-specific methylation changes often affected genes with roles in the regulation of transcription (49 genes, P=3.60×10^−10^), cell-cell signaling (17 genes, P=1.29×10^−5^) and cell surface receptor linked signal transduction (22 genes, P=0.042). Furthermore, by integrating TCGA gene expression data, it was identified that the methylation levels of 27 (20%), 23 (17%) and 45 (34%) CpGs exhibited strong, moderate and weak correlations with their gene expressions, respectively. Accordingly, among those that were strongly associated with DNA methylation (n=82), 64 genes (78%) were differentially expressed between tumor and non-tumor tissues. In summary, ADC-specific CGI loci, and those with corresponding gene expression aberrations in particular, may serve as potential biomarker candidates with diagnostic and prognostic possibilities.

### Identification of a novel CGI methylation signature that is a potent prognostic indicator for OS time in lung ADCs

Within the univariate Cox regression model incorporating methylation data of those ADCs-specific CGI loci, a total of 9 CGI CpGs were identified from the training set (TCGA-450k set) that were significantly associated with OS (permutation P≤0.05), and that had higher variability (SD≥0.10) in lung ADCs. Characteristics of the 9 CGI CpGs are summarized in [Table II](#tII-ol-0-0-10431){ref-type="table"}. Methylation data of 7 and 2 CpGs exhibited negative and positive associations with OS, respectively ([Table II](#tII-ol-0-0-10431){ref-type="table"}). Accordingly, as aforementioned, the risk score formula for the CpGs of the MyoD family inhibitor (*MDFI*), homeobox D3 (*HOXD3*), CKLF like MARVEL transmembrane domain containing 2 (*CMTM2*), paired box 3 (*PAX3*), LY6/PLAUR domain containing 5 (*LYPD5*), laeverin (*LVRN*), *RPL39L*, glutamate ionotropic receptor kainite type subunit 2 (*GRIK2*) and complexin 2 (*CPLX2*) genes was established as follows: Risk score=\[(1.403 × β-value of cg05345286 (MDFI)) + (1.564 × β-value of cg18702197 (*HOXD3*)) + (1.646 × β-value of cg01683883 (*CMTM2*)) + (1.526 × β-value of cg02245378 (*PAX3*)) + (0.984 × β-value of cg12768605 (*LYPD5*)) + (1.316 × β-value of cg25044651 (Laeverin (*LVRN*)) + (−1.130 × β-value of cg07693270 (*RPL39L*)) + (1.088 × β-value of cg26316946 (*GRIK2*)) + (−0.835 × β-value of cg19885761 (*CPLX2*))\]. On the basis of the risk formula, each patient from the TCGA-450k set was assigned a risk score, and then classified into low-risk or high-risk groups using the median score as a cut-off (3.08). Survival analysis indicated that in the TCGA-450k set, the low-risk group was associated with increased OS times compared with the high-risk group \[54.4 vs. 42.3 months, respectively; P=0.006 (log-rank test); [Fig. 1A](#f1-ol-0-0-10431){ref-type="fig"}\].

To confirm its prognostic relevance, the CGI methylation signature in an additional 2 datasets, the TCGA-27k and Robles *et al* ([@b11-ol-0-0-10431]) datasets, were analyzed. By directly applying the risk formula and using cut-off points, the TCGA-27k set was divided into a low-risk group (n=21) and a high-risk group (n=44). In concordance with the training set, patients within the low-risk group exhibited increased OS times compared with those within the high-risk group \[77.3 vs. 34.2 months; P=0.039 (log-rank test); [Fig. 1B](#f1-ol-0-0-10431){ref-type="fig"}\]. Similar results were also observed within the Robles *et al* ([@b11-ol-0-0-10431]) set, where low-risk patients were associated with improved OS compared with the high-risk patients \[median time not reached for either group; P=0.009 (log-rank test); [Fig. 1C](#f1-ol-0-0-10431){ref-type="fig"}\]. Pooled analysis at dataset level confirmed the prognostic relevance of the CGI methylation signature for lung ADCs \[hazard ratio (HR)=1.61, 95% confidence interval (CI), 1.20--2.17; P=0.002; I^2^=29%, P=0.25\].

Univariate Cox regression analysis of all patients from TCGA datasets (combined TCGA-27k and TCGA-450k sets) indicated that only tumor stages and the CGI methylation signature were significantly associated with OS, while patient age, sex, tumor stages, smoking status, MET proto-oncogene, receptor tyrosine kinase amplification and mutations in key genes including KRAS proto-oncogene, GTPase, Epithelial growth factor receptor, tumor protein P53 and B-Raf proto-oncogene, serine/threonine kinase were not. Finally, the multivariate Cox regression analysis demonstrated the prognostic significance of the CGI methylation signature of the present study in lung ADCs ([Table III](#tIII-ol-0-0-10431){ref-type="table"}).

### CGI methylation signature is not a strong prognostic indicator of RFS in lung ADCs

To investigate the association of the CGI methylation signature of the present study with RFS, it was analyzed within the TCGA-450k set, which yielded a marginally significant difference in RFS between each risk group \[33.9 vs. 27.0 months; P=0.049 (log-rank test); [Fig. 2A](#f2-ol-0-0-10431){ref-type="fig"}\]. Then, in the TCGA-27k set, low-risk patients appeared to exhibit longer RFS compared with the high-risk patients, but the difference did not reach significance (68.2 vs. 17.0 months; log-rank test P=0.072; [Fig. 2B](#f2-ol-0-0-10431){ref-type="fig"}). An additional large cohort of lung ADCs was finally introduced into the validation phase, where the CGI methylation signature also failed to significantly stratify patients into subgroups with distinct RFS outcomes \[62.6 vs. 55.6 months; P=0.492 (log-rank test); [Fig. 2C](#f2-ol-0-0-10431){ref-type="fig"}\]. Despite that, the pooled analysis of the 3 datasets yielded a significant difference in RFS between the risk groups (HR, 1.30; 95% CI, 1.04--2.62; P=0.020; I^2^=0%; P=0.38). The inconsistent results from different analysis levels indicated that the CGI methylation signature is not a robust indicator for RFS in lung ADCs.

### Novel classification approach based on the integration of DNA methylation and gene expression of RPL39L in lung ADCs

By characterizing each member of the CGI methylation panel, it was identified that one CGI locus (cg07693270) was consistently hypomethylated in lung ADCs ([Fig. 3A](#f3-ol-0-0-10431){ref-type="fig"}), and the methylation data were closely correlated with gene expression (*RPL39L*, Pearson coefficient r=−0.668; P\<0.0001; [Fig. 3B](#f3-ol-0-0-10431){ref-type="fig"}), indicating a methylation-dependent transcriptional regulatory mechanism for *RPL39L*. In line with its epigenetic status, *RPL39L* was upregulated in lung ADCs, indicating a tumor-promoting role ([Fig. 3C](#f3-ol-0-0-10431){ref-type="fig"}). At the initiation of the present study, the methylation level of *RPL39L* was positively correlated with OS. Therefore, the present study attempted to prognostically classify patients by single-locus methylation status of *RPL39L*, and it was identified that tumors with methylated CGI of *RPL39L* were associated with increased OS compared with the unmethylated tumors within TCGA samples ([Fig. 3D](#f3-ol-0-0-10431){ref-type="fig"}). Additionally, it was identified that based on *RPL39L* expression levels, patients may also be classified into distinct prognostic subgroups, in which tumors exhibiting decreased *RPL39L* expression levels were associated with increased OS time compared with those with increased expression levels \[59.7 vs. 42.7 months; P=0.002 (log-rank test); [Fig. 3E](#f3-ol-0-0-10431){ref-type="fig"}\]. These data indicated the possibility of a promising classification approach based on the integration of the DNA methylation and gene expression of *RPL39L*. Consequently, the present study identified that tumors with increased methylation and decreased expression of *RPL39L* exhibited the best OS among all cases ([Fig. 3F and G](#f3-ol-0-0-10431){ref-type="fig"}). The multivariate Cox model demonstrated the prognostic independence of the integrated approach (HR, 0.54; 95% CI, 0.36--0.81; P=0.003) as compared with tumor stages (HR, 1.66; 95% CI, 1.45--1.91; P\<0.001) within TCGA samples. These data indicated that *RPL39L* may serve oncogenic roles in the progression of lung ADCs, and may represent a novel promising therapeutic target for this disease. The integrated epigenetic and transcriptional assessment of *PRL39L* may be useful for optimizing the risk stratification of patients with lung ADC, and for identifying the appropriate subgroups sensitive to targeted drugs against *RPL39L*.

Discussion
==========

The study of epigenetic markers, particularly DNA methylation, represents one of the most promising and fastest expanding areas in cancer biomarker identification ([@b23-ol-0-0-10431]). Similar to other tumors, lung ADCs are characterized by distinct genome-wide DNA methylation landscapes, where the global hypomethylation of DNA repeats occurs concomitantly with CGI hypermethylation of gene regions ([@b8-ol-0-0-10431]). Among those cancer-specific DNA methylation aberrations, the promoter-specific CGI *de novo* methylation of tumor suppressor genes is the best-known epigenetic abnormality in lung cancer patients ([@b8-ol-0-0-10431]). Studies using candidate gene approaches have identified a large number of known tumor suppressors, including cyclin-dependent kinase inhibitor 2A ([@b24-ol-0-0-10431]), RAS association domain family member 1 ([@b25-ol-0-0-10431]), O-6-methylguanine-DNA methyltransferase ([@b26-ol-0-0-10431]) and APC, WNT signaling pathway regulator ([@b27-ol-0-0-10431]), to be consistently methylated in lung ADCs. A number of those epigenetic alterations were identified to serve crucial roles in tumorigenesis via the regulation of gene expression and to exhibit promise in the diagnosis and prognostication of patients with lung cancer ([@b24-ol-0-0-10431]--[@b27-ol-0-0-10431]). Previously, efforts have been made to comprehensively assess cancer epigenomes using genome-wide DNA methylation profiling techniques, including Illumina array-based assays, restriction landmark genome scanning gel-based analysis, and next-generation sequencing-based analysis ([@b23-ol-0-0-10431],[@b28-ol-0-0-10431]). The application of those high-throughput detection approaches may provide an unbiased and clear view of the lung cancer epigenome, and assist in identifying useful DNA methylation events for diagnostic and prognostic purposes.

The reproducibility of results from genome-wide DNA methylation analysis may be an issue for making definitive conclusions from these types of studies, as false-positive data are common in microarray analysis where the number of interrogated loci within each tumor is larger compared with the number of participants ([@b29-ol-0-0-10431]).

Batch effects appear to be a common phenomenon in high-throughput microarray data, particularly for the Infinium Methylation BeadChip ([@b13-ol-0-0-10431]). In the present study, the effective empirical Bayes method was adopted to remove the potential non-biological difference of methylation data across each dataset. Genome-wide DNA methylation data of lung ADCs and matched control tissues from 6 publically available datasets were then independently re-analyzed, and stricter criteria were adopted to identify robust cancer-specific CGI methylation loci in lung ADCs. In total, 134 cancer-specific CpGs were consistently observed in at least 4 of the 6 datasets examined in the present study, 11 of which had been described by previous studies with other DNA methylation detection approaches, for example genes in HOX clusters ([@b30-ol-0-0-10431]) including *HOXB4, HOXA7* and *HOXA9, TRIM58* ([@b31-ol-0-0-10431]) and *GALR1* ([@b32-ol-0-0-10431]) ([Table I](#tI-ol-0-0-10431){ref-type="table"}). The methylation status of these genes exhibited promise for the early detection and risk prediction for lung cancer ([@b30-ol-0-0-10431]--[@b32-ol-0-0-10431]). In addition, by integrating gene expression data, it was identified that a considerable proportion of these cancer-specific CGI methylation changes may have significant effects on their relevant gene expression, and indicate potential functional value in tumorigenesis of lung ADCs. Well-studied examples are the *de novo* CGI methylation of zinc finger protein 677 ([@b33-ol-0-0-10431]), cysteine dioxygenase type 1 ([@b34-ol-0-0-10431],[@b35-ol-0-0-10431]), SRY-box 1 (*SOX1*) ([@b36-ol-0-0-10431]) and *SOX17* ([@b37-ol-0-0-10431]) in NSCLCs. The data from the present study were corroborated by the validation of the identified CGI methylation candidates in the literature ([@b30-ol-0-0-10431]--[@b34-ol-0-0-10431]). In addition, the present study also identified a panel of previously unknown cancer-specific CGI methylation loci that may have potential roles in determining the fate of patients with lung cancer, which will warrant future investigation.

Clinically or functionally characterizing each CGI candidate is beyond the scope of the present study. Instead, by applying a univariate Cox regression model and permutation correction, a panel of 9 CGI CpGs that were significantly associated with OS time was identified in a large cohort of patients with lung ADCs (TCGA-450k set; n=450). The detection of a panel of biomarkers, compared with single markers, may have a higher sensitivity and specificity for specific clinical purposes ([@b38-ol-0-0-10431]). Therefore, a risk score-based prognostic classifier was established based on the methylation patterns of the 9 CpGs to assist in stratifying patients into distinct prognostic subgroups. The novel methylation signature indicated consistent prognostic ability in different patient cohorts. Finally, a multivariate Cox model demonstrated its prognostic significance in the context of different tumor stages. However, with respect to the RFS data, which is an additional notable clinical outcome, the novel methylation signature demonstrated limited value for risk stratification, and future validation is required for justifying a definitive conclusion. In summary, the data in the present study indicated that the CGI methylation signature of the present study may be a potent prognostic indicator for OS outcome in patients with all-stage lung ADCs. Additional supporting evidence for this novel CGI methylation signature may support its potential biological relevance in cancer biology. In the present study, it was identified that the methylation levels of 8 CpG loci were significantly correlated with gene expression (positively correlated: *HOXD3, GRIK2* and *PAX3*; and negative correlation: *PRL39L, CPLX2, CMTM2, LYPD5* and *LVRN*). Accordingly, the majority of the genes were differentially expressed between lung ADCs and normal tissues (upregulated: *RPL39L, GRIK2* and *HOXD3*; and downregulated: *CMTM2, CPLX2* and *LYPD5*). The majority of these genes have been demonstrated to be abnormally methylated and expressed in a number of human cancer types, including breast, colorectal and prostate cancer, and were closely associated with patient prognosis and tumor aggressiveness ([@b39-ol-0-0-10431]--[@b42-ol-0-0-10431]). However, limited data had been acquired on their functional roles in cancer biology. *RPL39L* was identified to confer drug resistance in lacrimal gland adenoid cystic carcinoma ([@b43-ol-0-0-10431]) and the lung cancer A549 cell line ([@b44-ol-0-0-10431]), but others have not been fully characterized in cancer. Future functional investigation of these genes will assist in developing understanding of the biological implications of the CGI methylation signature of the present study, and for identifying promising epigenetic therapeutic targets in lung ADCs.

Unlike the cancer-specific *de novo* DNA methylation at CGI regions of genes, the presence and functional roles of CGI hypomethylation have been much less well characterized in cancer biology. The present study identified that CGI hypomethylation of *RPL39L* was consistently observed in lung ADCs. This epigenetic event may have functional significance in the initiation and progression of lung cancer, as it markedly affected gene transcription and resulted in the upregulation of *RPL39L* in tumor tissues. In line with the aforementioned data, it was also demonstrated that within TCGA samples, either epigenetic or transcriptional activations of *RPL39L* were associated with poorer OS time in patients with lung ADCs. Furthermore, the integration of DNA methylation and gene expression data identified a refined subset of tumors with favorable prognoses whose *RPL39L* gene was epigenetically and transcriptionally repressed. *RPL39L* is a recently evolved ribosomal protein paralog that exhibits highly specific tissue expression patterns in mice and humans ([@b45-ol-0-0-10431]). This gene was previously described to be highly expressed in the testis and to be upregulated in multiple cancer cell lines ([@b45-ol-0-0-10431]). Wong *et al* ([@b45-ol-0-0-10431]) had demonstrated that *RPL39L* was highly upregulated in mouse embryonic stem cells, and that its expression was markedly associated with tumor aggressiveness and vascular invasiveness of hepatocellular carcinomas ([@b45-ol-0-0-10431]). High expression of *RPL39L* may also confer the drug-resistant phenotype of lung cancer A549 cell lines ([@b44-ol-0-0-10431]). However, *RPL39L* was demonstrated to be associated with hypermethylation and gene inactivation in prostate cancer cell lines ([@b39-ol-0-0-10431]). Together, these results indicated that epigenetic and transcriptional abnormalities in *RPL39L* were commonly implicated in the initiation and progression of human cancer. Notably, the data from the present study is of interest as it provides novel evidence for the contributing roles of CGI hypomethylation and gene re-activation in lung cancer. In addition, the data also raise concerns surrounding the current non-specific demethylating anticancer approach, as it may promote cancer development via the exacerbation of cancer-specific hypomethylation. Targeted epigenetic therapy that has distinct effects on cancer-specific hypermethylation and hypomethylation may be a promising option for the future development of anticancer therapy. Unfortunately, the oncogenic roles of *RPL39L* have not been studied extensively in lung ADCs. Future functional studies may assist in developing targeted therapies against this gene. Finally, the integrated assessment of *RPL39L* may be a promising approach for optimizing risk stratification, and improving personalized medicine in lung ADCs.

There were several limitations to the present study. The incompleteness of certain important clinical information for the included patients, including performance status and treatment modality, compromised the prognostic robustness of the study-specific methylation signature. The clinical and methodological heterogeneity across each dataset may also introduce uncertainty in data interpretation. Other limitations include the relatively small sample size of the validation sets, and the lack of functional validation of those CGI methylation candidates. The results of the present study were preliminary and primarily derived from microarray data analysis. Additional studies will be required to validate these results *in vivo*, and in a clinical setting.

In conclusion, by comparing genome-wide DNA methylation and gene expression profiles of lung ADCs and matched non-tumor tissues from multiple independent datasets, the present study identified a number of cancer-specific CGI methylation changes in lung ADCs, and characterized their associations with gene expression. Those CGI methylation changes may be useful for the identification of novel biomarkers for diagnostic and prognostic purposes in lung ADCs. One example is the identification of a 9-CpG methylation panel that was demonstrated to be a potent prognostic indicator for OS time. Furthermore, the identification of CGI hypomethylation and consequent gene re-activation of *RPL39L* provides novel insights into treatment development and risk stratification for lung ADCs.
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![Kaplan-Meier curves of overall survival time using the 9-CpG island methylation signature across each dataset. (A) TCGA-450k dataset. (B) TCGA-27k dataset. (C) Robles *et al* ([@b11-ol-0-0-10431]) dataset. TCGA, The Cancer Genome Atlas.](ol-18-02-1011-g00){#f1-ol-0-0-10431}

![Kaplan-Meier curves of the relapse-free survival time using the 9-CpG island methylation signature across each dataset. (A) TCGA-450k dataset. (B) TCGA-27k dataset. (C) Sandoval *et al* ([@b2-ol-0-0-10431]) dataset. TCGA, The Cancer Genome Atlas.](ol-18-02-1011-g01){#f2-ol-0-0-10431}

![Integration of DNA methylation and gene expression of *RPL39L* within The Cancer Genome Atlas samples. (A) Methylation status between matched lung adenocarcinomas and normal tissues. (B) Expression status between matched lung adenocarcinomas and normal tissues. (C) Pearson correlation between DNA methylation and *RPL39L* gene expression. (D) Patient classification on the basis of single-locus methylation levels of *RPL39L*. (E) Patient classification on the basis of the expression levels of *RPL39L*. (F) Patient classification on the basis of the combined assessment of DNA methylation and gene expression of *RPL39L*. (G) Patients with increased methylation and decreased expression of *RPL39L* experienced an improved survival time compared with that in the other subgroups. *RPL39L*, ribosomal protein 39 like; methy, methylated; unmethy, unmethylated.](ol-18-02-1011-g02){#f3-ol-0-0-10431}

###### 

Characteristics of the identified lung ADC-specific CpGs at CpG island regions.

  Probes       Chr.   Symbols      Gene ID   Association with CpG island   Association with gene region   Methylation status between tumor and normal tissues   Pearson coefficients between DNA methylation and gene expression^[a](#tfn1-ol-0-0-10431){ref-type="table-fn"}^   Log~2~ fold change between tumor and normal tissues^[b](#tfn2-ol-0-0-10431){ref-type="table-fn"}^
  ------------ ------ ------------ --------- ----------------------------- ------------------------------ ----------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------
  cg18335068   19     *ZNF677*     342926    Island                        5′UTR                          Hypermethylation                                      −0.603                                                                                                           −0.860
  cg08089301   17     *HOXB4*      3214      Island                        1stExon                        Hypermethylation                                      −0.536                                                                                                           −0.326
  cg04317399   7      *HOXA4*      3201      Island                        1stExon                        Hypermethylation                                      −0.492                                                                                                           −1.446
  cg07533148   1      *TRIM58*     25893     Island                        1stExon                        Hypermethylation                                      −0.475                                                                                                           −1.407
  cg07703401   16     *HBQ1*       3049      Island                        1stExon                        Hypermethylation                                      −0.461                                                                                                           −0.552
  cg23432345   7      *HOXA7*      3204      Island                        1stExon                        Hypermethylation                                      −0.436                                                                                                           −0.648
  cg12880658   5      *CDO1*       1036      Island                        1stExon                        Hypermethylation                                      −0.414                                                                                                           −1.599
  cg02919422   8      *SOX17*      64321     Island                        5′UTR                          Hypermethylation                                      −0.410                                                                                                           −1.527
  cg25875213   19     *ZNF781*     163115    Island                        5′UTR                          Hypermethylation                                      −0.402                                                                                                           −1.279
  cg14458834   17     *HOXB4*      3214      Island                        1stExon                        Hypermethylation                                      −0.389                                                                                                           −0.326
  cg10088985   4      *CXCL5*      6374      Island                        1stExon                        Hypermethylation                                      −0.375                                                                                                           −0.392
  cg04048259   20     *EDN3*       1908      Island                        TSS200                         Hypermethylation                                      −0.363                                                                                                           −1.415
  cg04062391   19     *ZNF560*     147741    Island                        5′UTR                          Hypermethylation                                      −0.341                                                                                                           Not Significant
  cg16428251   3      *SOX14*      8403      Island                        TSS200                         Hypermethylation                                      −0.341                                                                                                           Not Significant
  cg07621046   10     *C10orf82*   143379    Island                        TSS200                         Hypermethylation                                      −0.337                                                                                                           −0.355
  cg18536148   17     *TBX4*       9496      Island                        5′UTR                          Hypermethylation                                      −0.332                                                                                                           −1.540
  cg23290344   8      *NEFM*       4741      Island                        TSS1500                        Hypermethylation                                      −0.328                                                                                                           −0.336
  cg21233722   5      *DOCK2*      1794      Island                        Body                           Hypermethylation                                      −0.325                                                                                                           −0.946
  cg14384532   15     *NTRK3*      4916      Island                        TSS1500                        Hypermethylation                                      −0.322                                                                                                           −1.120
  cg02008154   7      *TBX20*      57057     Island                        1stExon                        Hypermethylation                                      −0.320                                                                                                           Not Significant
  cg21546671   17     *HOXB4*      3214      Island                        1stExon                        Hypermethylation                                      −0.319                                                                                                           −0.326
  cg19885761   5      *CPLX2*      10814     Island                        5′UTR                          Hypermethylation                                      −0.318                                                                                                           −0.476
  cg03734874   14     *TMEM179*    388021    Island                        TSS1500                        Hypermethylation                                      −0.313                                                                                                           0.530
  cg17525406   1      *AJAP1*      55966     Island                        Body                           Hypermethylation                                      −0.295                                                                                                           −0.943
  cg20616414   9      *WNK2*       65268     Island                        1stExon                        Hypermethylation                                      −0.288                                                                                                           0.946
  cg10235817   4      *ADRA2C*     152       Island                        1stExon                        Hypermethylation                                      −0.269                                                                                                           −1.000
  cg10141715   12     *SLC5A8*     160728    Island                        1stExon                        Hypermethylation                                      −0.254                                                                                                           −0.829
  cg00015770   4      *QRFPR*      84109     Island                        1stExon                        Hypermethylation                                      −0.246                                                                                                           Not Significant
  cg07536847   1      *PAX7*       5081      Island                        TSS1500                        Hypermethylation                                      −0.237                                                                                                           0.777
  cg25484904   4      *CWH43*      80157     Island                        TSS1500                        Hypermethylation                                      −0.237                                                                                                           −0.971
  cg13870866   7      *TBX20*      57057     Island                        1stExon                        Hypermethylation                                      −0.235                                                                                                           Not Significant
  cg06092815   2      *SPHKAP*     80309     Island                        TSS200                         Hypermethylation                                      −0.233                                                                                                           −0.977
  cg23710218   8      *MSC*        9242      Island                        1stExon                        Hypermethylation                                      −0.225                                                                                                           0.735
  cg12111714   13     *ATP8A2*     51761     Island                        Body                           Hypermethylation                                      −0.220                                                                                                           −1.184
  cg00548268   7      *NPTX2*      4885      Island                        TSS1500                        Hypermethylation                                      −0.215                                                                                                           0.843
  cg21376883   1      *ACTN2*      88        Island                        Body                           Hypermethylation                                      −0.213                                                                                                           −1.639
  cg08441806   10     *NKX6-2*     84504     Island                        1stExon                        Hypermethylation                                      −0.212                                                                                                           −0.576
  cg20959866   1      *AJAP1*      55966     Island                        TSS1500                        Hypermethylation                                      −0.211                                                                                                           −0.943
  cg00662556   18     *GALR1*      2587      Island                        Body                           Hypermethylation                                      −0.211                                                                                                           −0.322
  cg20792062   12     *KCNA5*      3741      Island                        5′UTR                          Hypermethylation                                      −0.211                                                                                                           −1.276
  cg10556064   16     *SMPD3*      55512     Island                        5′UTR                          Hypermethylation                                      −0.206                                                                                                           −0.405
  cg20291049   2      *POU3F3*     5455      Island                        1stExon                        Hypermethylation                                      −0.200                                                                                                           0.385
  cg12614105   7      *NPY*        4852      Island                        5′UTR                          Hypermethylation                                      −0.195                                                                                                           Not Significant
  cg09619146   10     *CPXM2*      119587    Island                        1stExon                        Hypermethylation                                      −0.193                                                                                                           Not Significant
  cg04490714   16     *SLC6A2*     6530      Island                        1stExon                        Hypermethylation                                      −0.190                                                                                                           −0.375
  cg13929328   10     *FOXI2*      399823    Island                        1stExon                        Hypermethylation                                      −0.189                                                                                                           −0.781
  cg18081258   14     *NDRG2*      57447     Island                        TSS1500                        Hypermethylation                                      −0.188                                                                                                           −1.450
  cg15343119   18     *GALR1*      2587      Island                        TSS1500                        Hypermethylation                                      −0.187                                                                                                           −0.322
  cg00891541   16     *SMPD3*      55512     Island                        5′UTR                          Hypermethylation                                      −0.187                                                                                                           −0.405
  cg10486998   18     *GALR1*      2587      Island                        TSS1500                        Hypermethylation                                      −0.187                                                                                                           −0.322
  cg21245652   2      *MAL*        4118      Island                        TSS1500                        Hypermethylation                                      −0.181                                                                                                           −1.204
  cg06675478   13     *SOX1*       6656      Island                        TSS200                         Hypermethylation                                      −0.178                                                                                                           0.352
  cg26721264   18     *GALR1*      2587      Island                        TSS1500                        Hypermethylation                                      −0.178                                                                                                           −0.322
  cg18952647   15     *BNC1*       646       Island                        TSS1500                        Hypermethylation                                      −0.177                                                                                                           −0.498
  cg01683883   16     *CMTM2*      146225    Island                        TSS1500                        Hypermethylation                                      −0.175                                                                                                           −1.336
  cg06722633   1      *GRIK3*      2899      Island                        Body                           Hypermethylation                                      −0.175                                                                                                           Not Significant
  cg25942450   5      *TLX3*       30012     Island                        TSS200                         Hypermethylation                                      −0.173                                                                                                           0.474
  cg27009703   7      *HOXA9*      3205      Island                        1stExon                        Hypermethylation                                      −0.170                                                                                                           Not Significant
  cg04534765   18     *GALR1*      2587      Island                        1stExon                        Hypermethylation                                      −0.170                                                                                                           −0.322
  cg19064258   16     *HS3ST2*     9956      Island                        1stExon                        Hypermethylation                                      −0.163                                                                                                           −0.265
  cg02164046   3      *SST*        6750      Island                        1stExon                        Hypermethylation                                      −0.159                                                                                                           Not Significant
  cg12768605   19     *LYPD5*      284348    Island                        TSS200                         Hypermethylation                                      −0.153                                                                                                           −0.346
  cg25720804   5      *TLX3*       30012     Island                        1stExon                        Hypermethylation                                      −0.153                                                                                                           0.474
  cg10883303   7      *HOXA13*     3209      Island                        1stExon                        Hypermethylation                                      −0.150                                                                                                           0.831
  cg12457773   6      *NRSN1*      140767    Island                        5′UTR                          Hypermethylation                                      −0.150                                                                                                           −0.521
  cg14008883   10     *SLC18A3*    6572      Island                        1stExon                        Hypermethylation                                      −0.148                                                                                                           0.725
  cg03544320   4      *CRMP1*      1400      Island                        1stExon                        Hypermethylation                                      −0.147                                                                                                           −0.610
  cg24199834   4      *POU4F2*     5458      Island                        1stExon                        Hypermethylation                                      −0.145                                                                                                           Not Significant
  cg19456540   14     *SIX6*       4990      Island                        1stExon                        Hypermethylation                                      −0.144                                                                                                           0.392
  cg08572611   7      *ACTL6B*     51412     Island                        Body                           Hypermethylation                                      −0.142                                                                                                           Not Significant
  cg00489401   5      *FLT4*       2324      Island                        Body                           Hypermethylation                                      −0.133                                                                                                           −1.340
  cg05373457   8      *KCNS2*      3788      Island                        5′UTR                          Hypermethylation                                      −0.133                                                                                                           Not Significant
  cg14991487   2      *HOXD9*      3235      Island                        TSS200                         Hypermethylation                                      −0.123                                                                                                           Not Significant
  cg02774439   4      *HAND2*      9464      Island                        5′UTR                          Hypermethylation                                      −0.122                                                                                                           −0.364
  cg02757432   10     *GPR26*      2849      Island                        1stExon                        Hypermethylation                                      −0.114                                                                                                           Not Significant
  cg25044651   5      *LVRN*       206338    Island                        1stExon                        Hypermethylation                                      −0.112                                                                                                           Not Significant
  cg01354473   7      *HOXA9*      3205      Island                        1stExon                        Hypermethylation                                      −0.112                                                                                                           Not Significant
  cg08109815   6      *NMBR*       4829      Island                        5′UTR                          Hypermethylation                                      −0.107                                                                                                           −0.506
  cg10303487   8      *DPYS*       1807      Island                        1stExon                        Hypermethylation                                      −0.107                                                                                                           −0.816
  cg18555440   11     *MYOD1*      4654      Island                        1stExon                        Hypermethylation                                      −0.094                                                                                                           Not Significant
  cg09936561   4      *DRD5*       1816      Island                        1stExon                        Hypermethylation                                      −0.085                                                                                                           Not Significant
  cg14859460   5      *GRM6*       2916      Island                        TSS200                         Hypermethylation                                      −0.079                                                                                                           Not Significant
  cg18722841   11     *PHOX2A*     401       Island                        1stExon                        Hypermethylation                                      −0.079                                                                                                           0.428
  cg09229912   12     *CUX2*       23316     Island                        1stExon                        Hypermethylation                                      −0.076                                                                                                           Not Significant
  cg20404387   1      *FAM43B*     163933    Island                        1stExon                        Hypermethylation                                      −0.072                                                                                                           0.314
  cg12782180   7      *LEP*        3952      Island                        TSS1500                        Hypermethylation                                      −0.070                                                                                                           0.987
  cg15489294   5      *LVRN*       206338    Island                        TSS1500                        Hypermethylation                                      −0.068                                                                                                           Not Significant
  cg25993718   20     *CBLN4*      140689    Island                        TSS200                         Hypermethylation                                      −0.067                                                                                                           −0.431
  cg16787600   10     *SORCS3*     22986     Island                        1stExon                        Hypermethylation                                      −0.062                                                                                                           Not Significant
  cg07307078   18     *TUBB6*      84617     Island                        TSS1500                        Hypermethylation                                      −0.059                                                                                                           −1.308
  cg08832227   12     *KCNA1*      3736      Island                        Body                           Hypermethylation                                      −0.058                                                                                                           −0.405
  cg01381846   7      *HOXA9*      3205      Island                        1stExon                        Hypermethylation                                      −0.055                                                                                                           Not Significant
  cg02332525   3      *GRM7*       2917      Island                        1stExon                        Hypermethylation                                      −0.050                                                                                                           −0.368
  cg15748507   10     *PRLHR*      2834      Island                        Body                           Hypermethylation                                      −0.049                                                                                                           Not Significant
  cg15191648   18     *SALL3*      27164     Island                        TSS200                         Hypermethylation                                      −0.048                                                                                                           0.690
  cg26609631   13     *GSX1*       219409    Island                        5′UTR                          Hypermethylation                                      −0.048                                                                                                           Not Significant
  cg13302823   8      *SCRT1*      83482     Island                        1stExon                        Hypermethylation                                      −0.033                                                                                                           Not Significant
  cg01839464   18     *DCC*        1630      Island                        Body                           Hypermethylation                                      −0.029                                                                                                           −1.162
  cg25691167   7      *FERD3L*     222894    Island                        1stExon                        Hypermethylation                                      −0.025                                                                                                           Not Significant
  cg05345286   6      *MDFI*       4188      Island                        Body                           Hypermethylation                                      −0.024                                                                                                           0.960
  cg25574024   11     *IGF2AS*     51214     Island                        Body                           Hypermethylation                                      −0.020                                                                                                           Not Significant
  cg11525285   14     *VSX2*       338917    Island                        1stExon                        Hypermethylation                                      −0.019                                                                                                           −0.269
  cg22187630   19     *CACNA1A*    773       Island                        1stExon                        Hypermethylation                                      −0.016                                                                                                           0.290
  cg21296230   15     *GREM1*      26585     Island                        5′UTR                          Hypermethylation                                      −0.010                                                                                                           1.327
  cg13791131   11     *IGF2AS*     51214     Island                        Body                           Hypermethylation                                      −0.009                                                                                                           Not Significant
  cg01295203   8      *PRDM14*     63978     Island                        TSS1500                        Hypermethylation                                      0.002                                                                                                            Not Significant
  cg26252167   6      *GPR6*       2830      Island                        1stExon                        Hypermethylation                                      0.004                                                                                                            Not Significant
  cg13547644   1      *ACTA1*      58        Island                        5′UTR                          Hypermethylation                                      0.012                                                                                                            Not Significant
  cg22881914   14     *NID2*       22795     Island                        TSS1500                        Hypermethylation                                      0.028                                                                                                            0.667
  cg23207990   4      *SFRP2*      6423      Island                        TSS1500                        Hypermethylation                                      0.041                                                                                                            0.729
  cg13323752   12     *SLC2A14*    144195    Island                        TSS200                         Hypermethylation                                      0.054                                                                                                            −0.701
  cg09643544   19     *ZNF177*     7730      Island                        1stExon                        Hypermethylation                                      0.064                                                                                                            −0.725
  cg08575537   7      *EPO*        2056      Island                        Body                           Hypermethylation                                      0.064                                                                                                            −0.262
  cg15107670   11     *WT1*        7490      Island                        1stExon                        Hypermethylation                                      0.067                                                                                                            0.569
  cg26186727   18     *NETO1*      81832     Island                        1stExon                        Hypermethylation                                      0.086                                                                                                            1.372
  cg06958829   17     *ACSF2*      80221     Island                        Body                           Hypermethylation                                      0.091                                                                                                            −0.500
  cg04907257   5      *ADCY2*      108       Island                        TSS1500                        Hypermethylation                                      0.097                                                                                                            −0.578
  cg21591742   2      *HOXD10*     3236      Island                        TSS1500                        Hypermethylation                                      0.114                                                                                                            0.507
  cg03958979   6      *NR2E1*      7101      Island                        TSS1500                        Hypermethylation                                      0.123                                                                                                            1.200
  cg02245378   2      *PAX3*       5077      Island                        Body                           Hypermethylation                                      0.126                                                                                                            Not Significant
  cg14144305   11     *ALX4*       60529     Island                        Body                           Hypermethylation                                      0.129                                                                                                            Not Significant
  cg25902889   19     *FSD1*       79187     Island                        Body                           Hypermethylation                                      0.141                                                                                                            0.842
  cg22660578   17     *LHX1*       3975      Island                        TSS1500                        Hypermethylation                                      0.151                                                                                                            0.784
  cg22341310   19     *ZNF541*     84215     Island                        Body                           Hypermethylation                                      0.172                                                                                                            −0.621
  cg13462129   7      *DLX5*       1749      Island                        Body                           Hypermethylation                                      0.193                                                                                                            0.678
  cg11376198   1      *AKR7L*      246181    Island                        TSS200                         Hypermethylation                                      0.243                                                                                                            0.531
  cg26316946   6      *GRIK2*      2898      Island                        1stExon                        Hypermethylation                                      0.246                                                                                                            0.659
  cg03874199   2      *HOXD12*     3238      Island                        TSS200                         Hypermethylation                                      0.283                                                                                                            0.501
  cg23130254   2      *HOXD12*     3238      Island                        1stExon                        Hypermethylation                                      0.317                                                                                                            0.501
  cg00767581   2      *HOXD4*      3233      Island                        TSS1500                        Hypermethylation                                      0.353                                                                                                            Not Significant
  cg18702197   2      *HOXD3*      3232      Island                        TSS1500                        Hypermethylation                                      0.355                                                                                                            0.422
  cg07693270   3      *RPL39L*     116832    Island                        5′UTR                          Hypomethylation                                       −0.668                                                                                                           1.296
  cg24898753   11     *FTH1*       2495      Island                        TSS1500                        Hypomethylation                                       0.053                                                                                                            −0.589
  cg06038133   17     *CORO6*      84940     Island                        Body                           Hypomethylation                                       0.054                                                                                                            −0.849

Pearson coefficients that were calculated using all TCGA lung ADC samples with paired DNA methylation and gene expression data.

Log2 fold changes that were calculated using the expression data from all paired lung ADCs and normal tissues from TCGA. TSS, transcription start site; UTR, untranslated region; TCGA, The Cancer Genome Atlas; ADC, adenocarcinoma; Chr., chromosome.

###### 

Characteristics of the 9-CpG CpG island methylation panel.

  Probe ID     Symbol     Association with gene region   Chr.   Methylation status between tumor and normal tissues^[a](#tfn3-ol-0-0-10431){ref-type="table-fn"}^   Expression status between tumor and normal tissues^[b](#tfn4-ol-0-0-10431){ref-type="table-fn"}^   Pearson coefficients between DNA methylation and gene expression^[c](#tfn5-ol-0-0-10431){ref-type="table-fn"}^   Univariate Cox coefficients^[d](#tfn6-ol-0-0-10431){ref-type="table-fn"}^   Permutation P-value^[d](#tfn6-ol-0-0-10431){ref-type="table-fn"}^
  ------------ ---------- ------------------------------ ------ --------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------- -------------------------------------------------------------------
  cg05345286   *MDFI*     Body                           6      Hyper                                                                                               Up                                                                                                 −0.024                                                                                                           1.403                                                                       0.003
  cg18702197   *HOXD3*    TSS1500                        2      Hyper                                                                                               Up                                                                                                 0.355                                                                                                            1.564                                                                       0.004
  cg01683883   *CMTM2*    TSS1500                        16     Hyper                                                                                               Down                                                                                               −0.175                                                                                                           1.646                                                                       0.012
  cg02245378   *PAX3*     Body                           2      Hyper                                                                                               NS                                                                                                 0.126                                                                                                            1.526                                                                       0.017
  cg12768605   *LYPD5*    TSS200                         19     Hyper                                                                                               Down                                                                                               −0.153                                                                                                           0.984                                                                       0.024
  cg25044651   *LVRN*     1stExon                        5      Hyper                                                                                               NS                                                                                                 −0.112                                                                                                           1.316                                                                       0.030
  cg07693270   *RPL39L*   5′UTR                          3      Hypo                                                                                                Up                                                                                                 −0.668                                                                                                           −1.130                                                                      0.043
  cg26316946   *GRIK2*    1stExon                        6      Hyper                                                                                               Up                                                                                                 0.246                                                                                                            1.088                                                                       0.043
  cg19885761   *CPLX2*    5′UTR                          5      Hyper                                                                                               Down                                                                                               −0.318                                                                                                           −0.835                                                                      0.049

Methylation status in all the 6 included datasets.

Expression status in all matched lung adenocarcinomas and normal tissues within the combined TCGA dataset (TCGA-27k and TCGA-450k sets).

Pearson coefficients in all TCGA tumor samples with paired DNA methylation and gene expression data.

Calculated within the TCGA-450k training set. Chr., chromosome; hyper, hypermethylation; hypo, hypomethylation; up, upregulation; down, downregulation; NS, not significantly altered; TCGA, The Cancer Genome Atlas; TSS, transcription start site; UTR, untranslated region; MDFI, MyoD family inhibitor; HOXD3, homeobox D3; CMTM2, CKLF like MARVEL transmembrane domain containing 2; PAX3, paired box 3; LYPD5, LY6/PLAUR domain containing 5; LVRN, laeverin; RPL39L, ribosomal protein 39 like; GRIK2, glutamate ionotropic receptor kainite type subunit 2; CPLX2, complexin 2.

###### 

Results from Cox regression models within all The Cancer Genome Atlas samples.

                              Univariate Cox model   Multivariate Cox model                          
  --------------------------- ---------------------- ------------------------ ---------------------- ---------
  Tumor stage                 1.651 (1.441--1.893)   \<0.001                  1.611 (1.405--1.847)   \<0.001
  CGI methylation signature   1.606 (1.199--2.152)   0.001                    1.449 (1.078--1.947)   0.014
  Sex                         1.057 (0.794--1.407)   0.705                    --                     --
  Smoking status              0.915 (0.611--1.371)   0.666                    --                     --
  Age                         1.009 (0.993--1.024)   0.271                    --                     --
  *BRAF* mutations            0.707 (0.402--1.246)   0.231                    --                     --
  *EGFR* mutations            1.230 (0.830--1.824)   0.302                    --                     --
  *KRAS* mutations            1.176 (0.858--1.610)   0.314                    --                     --
  *TP53* mutations            1.332 (0.990--1.793)   0.058                    --                     --
  *MET* amplification         1.027 (0.833--1.268)   0.801                    --                     --

HR, hazard ratio; CI, confidence interval; CGI, CpG island; BRAF, B-Raf proto-oncogene, serine/threonine kinase; EGFR, epithelial growth factor receptor; KRAS, KRAS proto-oncogene, GTPase; TP53, tumor protein P53; MET, MET proto-oncogene, receptor tyrosine kinase.

[^1]: Contributed equally
